SACM1L

Phosphatidylinositol-3-phosphatase SAC1 · Q9NTJ5 · SACM1L on Sugi Atlas →

0 patent compounds predicted against SACM1L, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SACM1L by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
Cardiovascular Effects of Empagliflozine nanUNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING
Immune Cell Response to Stimuli nanRECRUITING
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma nanSUSPENDED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
United States Hypophosphatasia Molecular Research Center nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SACM1L binder may also engage these)

ProteinNameSimilarity
Q5R921 1.000 Q5R921 →
A6QL88 1.000 A6QL88 →
Q6GM29 1.000 Q6GM29 →
Q9EP69 1.000 Q9EP69 →
A1L244 1.000 A1L244 →
Q9ES21 1.000 Q9ES21 →
Q7X911 0.999 Q7X911 →
Q96328 0.998 Q96328 →
A4VCH0 0.997 A4VCH0 →
O60162 0.996 O60162 →
Q9W0I6 0.996 Q9W0I6 →
P32368 0.992 P32368 →
Q55AW9 0.992 Q55AW9 →
O14127 0.991 O14127 →
Q9C5G5 0.991 Q9C5G5 →
Q8TGA2 0.988 Q8TGA2 →
P50942 0.988 P50942 →
O43001 0.988 O43001 →
Q8CHC4 0.988 Q8CHC4 →
Q9TXI7 0.987 Q9TXI7 →
Q9STV0 0.987 Q9STV0 →
Q92562 0.987 Q92562 →
Q8RXN5 0.987 Q8RXN5 →
Q8TGA1 0.987 Q8TGA1 →
Q9VV73 0.987 Q9VV73 →
C4Y206 0.987 C4Y206 →
A8E7C5 0.987 A8E7C5 →
O55207 0.987 O55207 →
P40559 0.987 P40559 →
Q6C710 0.987 Q6C710 →